Galderma Laboratories et al., 2024-10: The FDA-approved label for topical 1% ivermectin cream for inflammatory lesions of rosacea, applied once daily, evaluated in two identical randomized vehicle-controlled trials in 1371 subjects.
SOOLANTRA cream is indicated for the treatment of inflammatory lesions of rosacea.
1
Galderma Laboratories et al., 2024-10: The FDA-approved label for topical 1% ivermectin cream for inflammatory lesions of rosacea, applied once daily, evaluated in two identical randomized vehicle-controlled trials in 1371 subjects. Regulatory label. Section 14 states the two pivotal trials were 'randomized, double-blind, vehicle controlled', identical in design, 1371 subjects aged 18 and older, once daily for 12 weeks, 96% Caucasian, 67% female, comparator vehicle cream. Dosing per label: pea-size amount per facial area once daily, not for oral, ophthalmic or intravaginal use. Section 6 reports that 2047 subjects received the cream in clinical trials (safety population). Maker: Galderma. Pivotal publication is IVE-11 (Stein 2014). Study type: regulatory record.
